ストックスクリーナーアプリを入手
90.24
1.01%
0.90
プレマーケット:
93.23
2.99
+3.31%
Dianthus Therapeutics Inc (DNTH) 最新ニュース
LBL-047 Prioritized for Clinical Development in Sjögren's Disease, Systemic Lupus Erythematosus, and Dermatomyositis - GlobeNewswire Inc.
Dianthus Therapeutics (NASDAQ:DNTH) Releases Earnings Results, Beats Expectations By $0.25 EPS - MarketBeat
Dianthus Therapeutics : Quarterly Report for Quarter Ending March 31, 2026 (Form 10-Q) - marketscreener.com
Dianthus Therapeutics, Inc. (DNTH) Reports Q1 Loss, Lags Revenue Estimates - Yahoo Finance
Earnings Flash (DNTH) Dianthus Therapeutics, Inc. Reports Q1 Revenue $463K, vs. FactSet Est of $404K - marketscreener.com
Dianthus Therapeutics (NASDAQ: DNTH) builds $1.1B cash to fund autoimmune pipeline - Stock Titan
Dianthus got 20 responders before 40 patients in CIDP trial - Stock Titan
Dianthus (Nasdaq: DNTH) raises $719M, ends Q1 2026 with $1.2B cash - Stock Titan
Dianthus Therapeutics (DNTH) to Release Earnings on Monday - MarketBeat
MSN Money - MSN
Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Six new Dianthus hires get options to buy 135,000 shares - Stock Titan
Dianthus Therapeutics (DNTH) price target increased by 70.00% to 130.48 - MSN
Short Interest in Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Decreases By 27.6% - MarketBeat
Assessing Dianthus Therapeutics (DNTH) Valuation After FDA Trial Shift And Renewed Analyst Optimism - Yahoo Finance
BlackRock holds 2.63M Dianthus shares (NASDAQ: DNTH) — 5.1% stake - Stock Titan
Strength seen in Dianthus Therapeutics, Inc. (DNTH): Can its 5.6% jump turn into more strength? - MSN
Does Dianthus Therapeutics (DNTH) Trial Easing Quietly Redefine Its Long-Term Neuromuscular Strategy? - Sahm
Certain Stock Options of Dianthus Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 25-APR-2026. - marketscreener.com
Certain Warrants of Dianthus Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 25-APR-2026. - marketscreener.com
Dianthus Therapeutics announces proposed $400 million public share offering - MSN
Dianthus rises as FDA agrees with proposed changes to lead program - MSN
Dianthus Therapeutics Inc (DNTH): FDA Makes Trials Easier - Insider Monkey
5 Best 52-Week High US Stocks to Buy - Insider Monkey
Dianthus (DNTH) Investment Thesis | Dianthus Therapeutics Inc posts 30.3% EPS miss with no revenueHedge Fund Inspired Picks - Cổng thông tin điện tử Tỉnh Sơn La
Dianthus Therapeutics CFO Sells All Shares in 2026 Transaction | Company UpdateNews and Statistics - IndexBox
Dianthus Therapeutics' (DNTH) CFO Sold 8,224 Shares for $739,000 - AOL.com
Clear Street Initiates Buy on Dianthus Therapeutics, Inc. (DNTH) With $100 Price Target - MSN
Dianthus Therapeutics, Inc. (DNTH) Stock Analysis: Exploring a 35% Upside Potential Amid Biotech Innovations - DirectorsTalk Interviews
Dianthus Therapeutics (DNTH) Is Up 10.1% After $719M Raise And Insider Sale Has The Bull Case Changed? - Sahm
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Receives Consensus Recommendation of "Buy" from Analysts - MarketBeat
Dianthus Therapeutics CFO Sells $9.5 Million in Stock - AOL.com
Dianthus Therapeutics shares jump 25% after encouraging clinical trial update - MSN
Dianthus Therapeutics (NASDAQ:DNTH) Sets New 1-Year HighShould You Buy? - MarketBeat
Dianthus Therapeutics EVP Sells $10M in Shares - National Today
SG Americas Securities LLC Invests $765,000 in Dianthus Therapeutics, Inc. $DNTH - MarketBeat
DNTH SEC FilingsDianthus Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Dianthus Therapeutics (NASDAQ:DNTH) EVP Ryan Savitz Sells 8,224 Shares - MarketBeat
Ryan Savitz, Dianthus Therapeutics CFO, sells $738k in DNTH stock - Investing.com Canada
Dianthus Therapeutics Insider Sold Shares Worth $738,844, According to a Recent SEC Filing - marketscreener.com
Dianthus (NASDAQ: DNTH) CFO exercises options, sells 8,224 shares under 10b5-1 plan - Stock Titan
Dianthus Therapeutics Upgraded to Strong Buy at Wolfe Research - National Today
Dianthus Therapeutics (NASDAQ:DNTH) Upgraded by Wolfe Research to "Strong-Buy" Rating - MarketBeat
0.14%
0.48%
大文字化:
|
ボリューム (24 時間):